Stryker (SYK) Earnings Preview — Q3 2026
Key Factors to Watch for Q3 2026 Earnings
| Factor | Details & Context |
|---|---|
| Organic Sales Growth | Guidance narrowed to 8.3%–9.3% for FY26; Q3 must deliver strong growth after a cyber-impacted Q1. |
| Peripheral Vascular Recovery | Ongoing supply chain issues in Inari/peripheral vascular; management expects continued drag in Q3. |
| Ortho (Hips/Knees) Volumes | Joint replacement, especially hips, softer than expected in Q2; watch for signs of recovery. |
| Capital Equipment Backlog | Order book remains strong; ability to ramp production and convert backlog is critical. |
| Margin Expansion | Commitment to +150 bps over 3 years; Q2 saw strong margin, but cyber costs and tariffs are factors. |
| New Product Launches | Full launches of Mako RPS, Triathlon Gold, Incompass Ankle, Pangea in Europe, SONOPET 3 upcoming. |
| Share Repurchases | Company plans to resume buybacks in H2 2026; $1B authorized. |
| Macro/Procedure Volumes | Management sees stable US procedure environment; Europe softer, especially in joint replacement. |
Summary and Conclusions
- Q3 2026 is a pivotal quarter: Stryker must deliver a strong rebound in organic sales growth to meet its narrowed FY26 guidance (8.3%–9.3%). The company is coming off a cyberattack-disrupted Q1 and a solid Q2 (+9.0% organic), but faces ongoing headwinds in peripheral vascular and softness in joint replacement, especially hips.
- Peripheral vascular (Inari) remains a drag: Supply chain issues are not yet resolved and are expected to continue into Q3, with management confirming a ~70–80 bps drag on total company growth in Q2 and similar impact expected in Q3.
- Capital equipment demand is robust: Backlog and order book remain strong, especially in Medical (beds, Smart Care), but the key question is whether Stryker can ramp production fast enough to convert backlog into revenue in H2.
- Margins and EPS: Q2 saw strong adjusted operating margin (27.4%, +170 bps YoY) and EPS ($3.69, +17.9%), aided by tariff refunds. However, cyber-related costs and ongoing remediation will pressure margins in H2. Management remains committed to its +150 bps margin expansion target over three years.
- Product launches and innovation: Several new products are ramping or launching in H2 (Mako RPS, Triathlon Gold, Incompass Ankle, Pangea EU, SONOPET 3). Execution on these launches is a key upside lever.
- Share repurchases: Stryker will resume buybacks in H2 2026, with $1B authorized, reflecting strong cash flow and limited near-term M&A.
- Comparables: Q3 2025 was a strong quarter (+9.5% organic sales growth), so the company faces a tough YoY comp.
Recent Results — Quarterly Financials
Quarterly Actuals (Reported Revenue, Adjusted EPS, Organic Sales Growth)
| Quarter | Revenue ($M) | Organic Sales Growth | Adjusted EPS ($) | Adjusted Op Margin (%) |
|---|---|---|---|---|
| Q2 2026 | 6,589 | 9.0% | 3.69 | 27.4 |
| Q1 2026 | 6,020 | 2.4% | 2.60 | 21.1 |
| Q4 2025 | 7,171 | 11.0% | 4.47 | 30.2 |
| Q3 2025 | 6,057 | 9.5% | 3.19 | 25.6 |
Note: Q1 2026 was impacted by a cyber incident, resulting in a sharp deceleration in growth and margin.
Forward Consensus Estimates
| Quarter | Revenue Consensus ($M) | EPS Consensus ($) |
|---|---|---|
| Q3 2026 | 6,638 | 3.16 |
| Q4 2026 | 7,977 | 4.71 |
| Fiscal Year | Revenue Consensus ($M) | EPS Consensus ($) |
|---|---|---|
| 2026 | 27,222 | 12.86 |
FY26 Guidance (as of Q2 2026)
| Metric | Guidance Range | Notes |
|---|---|---|
| Organic Net Sales Growth | 8.3% – 9.3% | Narrowed from 8.0%–9.5%; reflects strong H2 ramp needed |
| Adjusted EPS | $14.95 – $15.10 | No change to upper end; Q2 beat aided by tariff refunds |
| Adjusted Op Margin | +150 bps over 3 years | Commitment unchanged; cyber costs and tariffs are factors |
| Pricing Impact | Modestly positive | MedSurg positive, Ortho slightly negative |
| FX Impact | Slightly favorable | If rates hold near current levels |
| Other Income/Expense | ~$420M | Unchanged |
| Tax Rate | 15%–16% | Unchanged |
Q3 2026 Preview — What Matters Most
1. Organic Sales Growth Trajectory
- Q3 must deliver high single-digit to low double-digit organic growth to keep FY guidance achievable.
- Q3 2025 comp was +9.5% organic, so YoY comparison is tough.
2. Peripheral Vascular (Inari) Recovery
- Ongoing supply chain issues are expected to persist into Q3, with management guiding for continued drag (~70–80 bps on total company growth).
- Watch for commentary on timing of full recovery and ability to regain lost share.
3. Ortho (Hips/Knees) Volumes
- Hips particularly soft in Q2, both in US and Europe; management notes normal seasonality but slower than expected summer.
- September is typically a strong month; any sign of pent-up demand release will be important.
4. Capital Equipment Conversion
- Backlog/order book remains strong, especially in Medical (beds, Smart Care).
- Execution on production ramp and conversion of backlog into revenue is critical for H2.
5. Margin Progression
- Q2 margin benefited from tariff refunds; cyber costs and remediation will pressure H2.
- Management remains committed to +150 bps margin expansion over three years.
6. New Product Launches
- Full commercial launches of Mako RPS, Triathlon Gold, Incompass Ankle, Pangea in Europe, and SONOPET 3 are all expected to contribute in H2.
- Execution and uptake will be key for upside.
7. Share Repurchases
- Stryker will resume buybacks in H2 2026, with $1B authorized; signals strong cash flow and limited near-term M&A.
How Did They Report Last Year? (Q3 2025)
| Quarter | Revenue ($M) | Organic Sales Growth | Adjusted EPS ($) | Adjusted Op Margin (%) |
|---|---|---|---|---|
| Q3 2025 | 6,057 | 9.5% | 3.19 | 25.6 |
- Q3 2025 was a strong quarter, with +9.5% organic sales growth and double-digit adjusted EPS growth.
- The company faced a tough comp for Q3 2026.
Management Commentary — Recent Tone
- On Guidance: "We are narrowing our full year guidance and now expect organic net sales growth to be in the range of 8.3% to 9.3% and adjusted net earnings per share to be in the range of $14.95 to $15.10."
- On Peripheral Vascular: "Peripheral vascular isn't quite seeing that same recovery that we would have expected from a supply standpoint...we do anticipate the third quarter to be very similar to second quarter in terms of the impact of PV on the growth rate."
- On Ortho: "Our joint replacement business is a little bit slower in terms of than what we anticipated heading into the third quarter...certainly a little bit slower than what we anticipated leaving the second quarter."
- On Capital: "Our backorder remains really strong. The order book remains strong for those capital products."
- On Margins: "We are still committed to what we talked about last year, which is our 150 basis points over the course of 3 years."
Conclusion
- Q3 2026 is a critical quarter for Stryker. The company must demonstrate a strong rebound in organic sales growth and margin progression to keep FY guidance in play, despite ongoing headwinds in peripheral vascular and joint replacement.
- Key focus areas: Peripheral vascular supply recovery, joint replacement volumes (especially hips), capital equipment conversion, and execution on new product launches.
- Watch for: Any updates on supply chain normalization, backlog conversion, and margin trajectory, as well as commentary on macro headwinds (hospital budgets, ACA/340B, inflation).
- Comparables: Q3 2025 was a strong quarter, so the YoY comp is challenging.
Bottom line: Stryker needs to execute on production ramp, resolve supply chain issues in peripheral vascular, and see a pickup in joint replacement volumes to deliver on its narrowed FY26 guidance. The company’s strong backlog and diversified portfolio provide support, but execution risk remains elevated for H2 2026.
